Publications by authors named "G Tryggvason"
Article Synopsis
- Researchers analyzed genetic data from nearly 130,000 cancer patients and over 730,000 healthy controls to identify variants linked to cancer risk across 22 cancer types.
- Four high-risk genes were found: BIK (prostate cancer), ATG12 (colorectal cancer), TG (thyroid cancer), and CMTR2 (lung cancer and melanoma).
- Additionally, two genes, AURKB (general cancer risk) and PPP1R15A (breast cancer), were associated with decreased cancer risk, indicating potential pathways for cancer prevention strategies.
Nano and microfluidic technologies have shown great promise in the development of controlled drug delivery systems and the creation of microfluidic devices with logic-like functionalities. Here, we focused on investigating a droplet-based logic gate that can be used for automating medical diagnostic assays. This logic gate uses viscoelastic fluids, which are particularly relevant since bio-fluids exhibit viscoelastic properties.
View Article and Find Full Text PDFNumerical solution of partial differential equations on parallel computers using domain decomposition usually requires synchronization and communication among the processors. These operations often have a significant overhead in terms of time and energy. In this paper, we propose communication-efficient parallel algorithms for solving partial differential equations that alleviate this overhead.
View Article and Find Full Text PDFBackground: Tracheostomies are commonly utilized in ICU patients due to prolonged mechanical ventilation, upper airway obstruction, or surgery in the face/neck region. However, practices regarding the timing of placement and utilization vary. This study provides a nationwide overview of tracheostomy utilization and outcomes in the ICU over a 14-year period.
View Article and Find Full Text PDFBackground: Although epistaxis is one of the most common side effects of oral anticoagulation, it is unclear whether epistaxis rates vary between different oral anticoagulants (OAC).
Objective: To compare rates of clinically relevant epistaxis between OAC.
Methods: Epistaxis event rates were compared between new users of apixaban, dabigatran, rivaroxaban, and warfarin in a nationwide population-based cohort study over a 5-year study period, 2014-2019.